--- title: "The GLP-1 trend: What the real-world data reveals" description: GLP-1 prescriptions have surged 587%. Discover what the data reveals about prescribing trends and how HealthVerity supports post-market research. image: https://blog.healthverity.com/hubfs/glp-1-surge-rwd-blog%E2%80%93alt-2.png --- Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/) - [Contact](https://healthverity.com/contact/) - [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/) [![HealthVerity-Logo-Dark-3](https://blog.healthverity.com/hs-fs/hubfs/HealthVerity-Logo-Dark-3.png?width=1662&height=320&name=HealthVerity-Logo-Dark-3.png)](https://healthverity.com/) - How We Help - Featured Content - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Life Sciences](https://healthverity.com/life-sciences/) - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - Data Ecosystem - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/) - [Media Measurement](https://healthverity.com/media-measurement/) - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/) - Technology Products - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - [HealthVerity FLOW](https://healthverity.com/flow/portal/) - [Governance Manager](https://healthverity.com/governance-manager/) - [Smart Contracts](https://healthverity.com/smart-contracts-manager/) - Symphony - Symphony Health Platform - [Symphony Health Overview](https://healthverity.com/symphony-health/overview/) - [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - Symphony Solutions - [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/) - [HealthRankings](https://healthverity.com/symphony-health/health-rankings/) - [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/) - [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/) - [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/) - Symphony Products - [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf) - [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf) - [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf) - [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf) - [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf) - [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf) - [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf) - [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf) - Symphony Technology - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf) - [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/) - Who We Serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) - Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) - [Zombie Data Explained](https://healthverity.com/get-verified/) - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) [Contact](https://healthverity.com/contact/) [Sign In](https://marketplace.healthverity.com/) [![Logo](https://blog.healthverity.com/hubfs/social-suggested-images/healthverity.comwp-contentuploadshealthverity-2023-logo2x.png)](https://healthverity.com/) - How We Help - Symphony - Who We Serve - Resources - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) Featured Content ###### HealthVerity MarketplaceTM The nation’s largest healthcare and consumer data ecosystem ###### taXonomy Pathways Unique features per therapeutic area with claims, labs and EHR including notes ###### HealthVerity eXOs AI-native real-world evidence generation ###### Identity Manager (HVID) Standalone de-identification as a service Data Ecosystem HealthVerity MarketplaceTM HealthVerity TaxonomySM HealthVerity Notes Precision Event Alerts HealthVerity Mastersets Media Measurement Syndicated Audiences Insurance Underwriting Technology Products Identity Manager (HVID) HealthVerity for Clinical Trial Linkage HealthVerity for Commercial Smart Contracts HealthVerity for Registries Symphony Health Platform ###### Symphony Health Overview Seamless Data. Stronger Insights. Smarter Decisions. ###### Integrated Dataverse Integrated Dataverse (IDV®) is de-identified claims data platform that combines medical, hospital, prescription, and demographic data into a single unifed view. ###### Symphony HealthCloud Securely store, integrate, access, and analyze virtually unlimited volumes of data with Symphony HealthCloud. Symphony Solutions Health technology and business intelligence solutions Integrated Dataverse and Source Solutions Brand strategy and sales HealthRankings Market access Patient Journey Medicines affordability Symphony Products PayerSource® PrescriberSource® PatientSource® PatientSourceCompleteTM PatientSourceDUOTM Symphony FLEXTM CustomerSource® DiagnosticSource® NonRetailSource® Symphony Technology Symphony HealthCloud Synoma Data Integration Vantage Applications Metys ###### Life Sciences Technology solutions from development through commercialization ###### Channel Partners HealthVerity enables partners to unlock unprecedented value and insights for clients ###### Government Comprehensive and compliant solutions to manage the nation’s care ###### Data Ecosystem Partners Join the nation’s largest data partner ecosystem ###### Insurance Insurance-grade solutions that excel in managing risk and rebates ###### HealthVerity Blog Insights and updates from industry experts ###### Publications Peer-reviewed research and discoveries ###### News & Events Stay informed about our latest announcements and happenings ###### The IPGE Approach Fundamentals that power everything that we do and every solution we offer ###### Resource Library Explore guides, webinars, and tools to enhance your understanding ###### Zombie Data Explained Learn how data quality drives better research outcomes [Trends & Insights](https://blog.healthverity.com/tag/trends-insights), [Marketplace](https://blog.healthverity.com/tag/marketplace) # The GLP-1 trend: What the real-world data reveals [By - Laura Budurlean, PhD, Content Marketing Manager,](https://blog.healthverity.com/author/laura-budurlean) June 16, 2025 ![](https://blog.healthverity.com/hubfs/glp-1-surge-rwd-blog%E2%80%93alt-2.png) ## GLP-1 Trends: Ozempic and Semaglutide drive a 587% spike in prescriptions Prescriptions for GLP-1 receptor agonists, including Ozempic, Semaglutide, and Rybelsus, have surged over the last five years as their effectiveness in promoting weight loss gains attention beyond type 2 diabetes care. According to FAIR Health, prescriptions for GLP-1 drugs to treat overweight or obesity rose 587% from 2019 to 2024. The number of adults prescribed a GLP-1 without a type 2 diabetes diagnosis jumped nearly 1,961% during the same period (Figure 1).1  ![glp1 use-1](https://blog.healthverity.com/hs-fs/hubfs/glp1%20use-1.png?width=687&height=410&name=glp1%20use-1.png) Figure 1: GLP-1 trends since 2019, created using data from FAIR Health study.1 ## HealthVerity Marketplace tracks over 19.1 million GLP-1 patients and 790,000 providers [HealthVerity Marketplace](https://healthverity.com/marketplace/healthverity-marketplace/) offers real-time visibility into one of the most significant pharmaceutical shifts in decades. Through linked, privacy-compliant pharmacy records, HealthVerity Marketplace includes prescription records on approximately 19.1 million patients taking GLP-1 drugs such as Ozempic, Semaglutide, and Rybelsus. These records also offer unique insight into how much weight patients lose on GLP-1s like Ozempic in real-world settings, aligning with current interest in GLP-1 weight loss trends. It also includes information on more than 790,000 prescribing providers by NPI making it one of the most comprehensive GLP-1 analytics sources available today. The recent [combination of HealthVerity and Symphony Health](https://healthverity.com/symphony-health/) expands these capabilities even further. Together, they create the industry's largest single source of U.S. healthcare data, bringing pharmacy, medical claims, laboratory and electronic health record (EHR) data into one privacy-protected ecosystem. This gives life sciences organizations a more comprehensive view of patient and provider journeys across clinical development, real-world evidence and commercial strategy. For organizations studying GLP-1 therapies, that means richer longitudinal patient journeys, broader population coverage and greater confidence in understanding prescribing patterns, treatment persistence, clinical outcomes and market dynamics.  ### This real-world data can support a range of use cases: - **Post-market surveillance:** Monitor side effects, switching behavior, and persistence over time across diverse patient populations. - **Health economics and outcomes research (HEOR):** Evaluate cost-effectiveness, resource utilization, and outcomes compared to other interventions like bariatric surgery. - **Provider and prescriber insights:** Identify prescribing patterns, top prescribers, and geographic variation in clinical decision-making. - **Patient journey analysis:** Map the timeline from diagnosis to treatment to assess how real-world behavior compares with clinical guidelines. - **Targeted education and outreach:** Inform provider engagement strategies with de-identified real-world data on therapeutic adoption and usage trends. HealthVerity enables pharmaceutical manufacturers to go beyond traditional claims analysis by delivering verified, linked insights into how GLP-1 drugs are being used across populations. To see more Marketplace data in action [read our blog on the link between prostate cancer and mental health](https://blog.healthverity.com/prostate-cancer-mental-health-the-importance-of-real-world-insights) ### Younger adults are driving GLP-1 demand while bariatric surgery declines The trend is especially sharp among young adults. GLP-1 prescriptions for those aged 18 to 39 increased 588%, from 0.19% in 2019 to 1.33% in 2024.1 During the same period, the rate of bariatric surgeries fell by nearly 42%, indicating a shift in how patients and physicians are managing obesity. ### Why GLP-1 success in the real world looks different than in trials In the evolving landscape of GLP-1 trends, Ozempic (semaglutide) has garnered attention for its weight loss effects. While individual results vary, studies indicate that patients may experience an average weight loss of 5 to 10 pounds per month, especially after the initial dosing period. Factors influencing this include dosage, adherence to treatment, lifestyle modifications, and baseline body weight. These insights underscore the significance of GLP-1 receptor agonists in weight management strategies. GLP-1 therapies like Ozempic and Wegovy showed promising weight loss outcomes in trials, but real-world usage is proving more complex. One study found patients who stopped taking the drugs early lost only 3.6% of their body weight. Those who remained on therapy for a full year lost about 12%, falling short of clinical trial averages of 15 to 20%². Side effects, cost, and insurance coverage were cited as key barriers to adherence. ### Most eligible patients still aren't receiving GLP-1 medications Even as GLP-1 trends climb, most people diagnosed with overweight or obesity are not receiving prescriptions. In 2024, only 11.2% of patients with these diagnoses were prescribed a GLP-1 drug. Meanwhile, 6.3% received behavioral health services, and only 0.28% had bariatric surgery.1 This unmet need underscores the importance of accurate targeting and real-world insights. The GLP-1 market is moving fast. Your strategy should too. Explore how [HealthVerity Marketplace](https://healthverity.com/marketplace/healthverity-marketplace/) can help you measure outcomes, identify safety signals, and define patient journeys in real time. [![Explore real-world data in HealthVerity Marketplace ](https://no-cache.hubspot.com/cta/default/5412465/interactive-192965525172.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIXwMMLnjU8QDteJuMKkTULan5rIl%2FLWx%2BfsUaqQP4wYB5tcuCwiVVC7IsL94H7aQDlFpmSj1m76aZ%2FHA%2FI37M0yLfBbCaSMUNju7mjTaN6BdWNpiCdaGSv5wR%2F4XZbWMK3tTJEtvcbki5encoVnyBwcjisNg6J1hEr734aDl4hS8ykFht7Fz10SNgE%2B8MZqIiZz3uCxbU%2Bt0k7Q0LNNUkE&webInteractiveContentId=192965525172&portalId=5412465) ### References 1. FAIR Health. Use of GLP-1 Drugs to Treat Overweight or Obesity Increased 587 Percent from 2019 to 2024, According to New FAIR Health Study. May 27, 2025. Accessed June 11, 2025. [https://www.fairhealth.org/press-release/use-of-glp-1-drugs-to-treat-overweight-or-obesity-increased-587-percent-from-2019-to-2024-according-to-new-fair-health-study](https://www.fairhealth.org/press-release/use-of-glp-1-drugs-to-treat-overweight-or-obesity-increased-587-percent-from-2019-to-2024-according-to-new-fair-health-study) 2. Reuters. Health Rounds: Patients drop fewer pounds with weight-loss drugs in real world than in trials. June 11, 2025. Accessed June 11, 2025. [https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-patients-drop-fewer-pounds-with-weight-loss-drugs-real-world-than-2025-06-11/](https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-patients-drop-fewer-pounds-with-weight-loss-drugs-real-world-than-2025-06-11/) [![HealthVerity and Symphony Health — the largest RWD data ecosystem](https://no-cache.hubspot.com/cta/default/5412465/interactive-214690873935.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLK74gKZwGiPpIxqEJTMX%2B3I%2BpzInqYjhYYuv82wbe5ptMM64jHq8u4lZXuF2MGjF6LgnSsWPURiJIP7giUSJ1SVL7XisygZHcnh0tkhxao5tIIa3s71ewjKEFmemavweu7wDED%2F1lNJXAsvRgimwD1UVj7BjxrZufcOut4lotqi71Q1pJtwkUg%3D&webInteractiveContentId=214690873935&portalId=5412465) [![Explore RWD in HealthVerity Marketplace™](https://no-cache.hubspot.com/cta/default/5412465/interactive-195733501532.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLIxJEuNiSD9iw0pfP5mE9cy9gfktIVRpAvCKCef8E41gjaw%2FR1iN6hTvcuHvjSQErX3FAUpnVy3buoDmwlUq54wiJljGzrw7fAvqDxmZDgROeH4uIA2bx5CDRV%2B3juceVFS7P4m7rozT6bN28iOz94ZFQWmWyBylv3ACiT%2BQpKvNTN1cfSO8V4%3D&webInteractiveContentId=195733501532&portalId=5412465) ###### Category - [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices) - [Trends & Insights](https://blog.healthverity.com/tag/trends-insights) - [HEOR](https://blog.healthverity.com/tag/heor) - [Marketplace](https://blog.healthverity.com/tag/marketplace) - [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership) - [taXonomy](https://blog.healthverity.com/tag/taxonomy) - [Industry Updates](https://blog.healthverity.com/tag/industry-updates) - [Case Studies](https://blog.healthverity.com/tag/case-studies) - [Government](https://blog.healthverity.com/tag/government) - [Commercial Pharmaceutical](https://blog.healthverity.com/tag/commercial-pharmaceutical) - [AI](https://blog.healthverity.com/tag/ai) - [eXOs](https://blog.healthverity.com/tag/exos) - [Audiences](https://blog.healthverity.com/tag/audiences) - [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways) - [Notes](https://blog.healthverity.com/tag/notes) - [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases) ###### Popular Post - [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) - [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) - [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims) - [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) - [What is Privacy Preserving Record Linkage (PPRL)?](https://blog.healthverity.com/what-is-privacy-preserving-record-linkage) ###### Subscribe ### Similar Blogs [![What is Privacy Preserving Record Linkage (PPRL)?](https://blog.healthverity.com/hs-fs/hubfs/22-08-31%20PPRL%20Blog%20Post-1.png?width=352&name=22-08-31%20PPRL%20Blog%20Post-1.png)](https://blog.healthverity.com/what-is-privacy-preserving-record-linkage) #### [What is Privacy Preserving Record Linkage (PPRL)?](https://blog.healthverity.com/what-is-privacy-preserving-record-linkage) [Emery Niemiec](https://blog.healthverity.com/author/emery-niemiec) 1 September 2022 Author: Emery Niemiec, Director, Partners & Alliance at HealthVerity [READ MORE](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) [![Synchronizing real-world data to better protect public health](https://blog.healthverity.com/hs-fs/hubfs/synchronizing-real-world-data-to-better-protect-public-health-1.jpg?width=352&name=synchronizing-real-world-data-to-better-protect-public-health-1.jpg)](https://blog.healthverity.com/synchronizing-real-world-data-to-better-protect-public-health) #### [Synchronizing real-world data to better protect public health](https://blog.healthverity.com/synchronizing-real-world-data-to-better-protect-public-health) [HealthVerity](https://blog.healthverity.com/author/healthverity) 9 August 2023 As we venture further into the digital age, there is a proliferation of data available today that,... [READ MORE](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) [![What is PPRL? A smarter way to link data securely and accurately](https://blog.healthverity.com/hs-fs/hubfs/ask-an-expert-blog-featured-alt-5.png?width=352&name=ask-an-expert-blog-featured-alt-5.png)](https://blog.healthverity.com/what-is-pprl-a-smarter-way-to-link-data-securely-and-accurately) #### [What is PPRL? A smarter way to link data securely and accurately](https://blog.healthverity.com/what-is-pprl-a-smarter-way-to-link-data-securely-and-accurately) [Emery Niemiec, Principal Government Sales](https://blog.healthverity.com/author/emery-niemiec-principal-government-sales) 31 July 2025 In this edition of our Ask an Expert series, we turn to Emery Niemiec, Senior Director,... [READ MORE](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) #### Who we serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) #### How we help - [HealthVerity Marketplace](https://healthverity.com/marketplace/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/) - [HealthVerity FLOW](https://healthverity.com/flow/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) #### Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) #### Our company - [About Us](https://healthverity.com/about-us/) - [Leadership](https://healthverity.com/about-us/#leadership) - [Board of Directors](https://healthverity.com/about-us/#board) - [Careers](https://healthverity.com/careers/) - [Contact](https://healthverity.com/contact/) ©2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/) ![](https://px.ads.linkedin.com/collect/?pid=4361946&fmt=gif) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Laura Budurlean, PhD" }, "datePublished" : "2025-06-16", "description" : "Explore the surging demand for GLP-1 drugs like Ozempic and Semaglutide. Real-world data reveals a 587% spike in prescriptions, declining bariatric surgery rates, and the gap between clinical trial weight loss and real-world results.", "headline" : "The GLP-1 trend: What the real-world data reveals", "keywords" : [ "GLP-1 trends", "Ozempic weight loss", "Semaglutide", "real-world data", "RWE", "bariatric surgery decline", "obesity treatments", "healthcare analytics", "GLP-1 adherence" ], "mainEntityOfPage" : { "@id" : "https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://healthverity.com/wp-content/uploads/2023/08/healthverity-logo.png" }, "name" : "HealthVerity" } } ``` ```json { "@context" : "https://schema.org", "@type" : "FAQPage", "mainEntity" : [ { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Prescriptions for GLP-1 receptor agonists, such as Ozempic and Semaglutide, surged dramatically. According to FAIR Health data, prescriptions for GLP-1 drugs to treat overweight or obesity rose 587% from 2019 to 2024. Prescriptions for adults without a type 2 diabetes diagnosis jumped by nearly 1,961% during the same period." }, "name" : "How much have GLP-1 prescriptions increased recently?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "As demand for GLP-1 medications has skyrocketed—particularly driven by young adults ages 18 to 39—the rate of bariatric surgeries fell by nearly 42% between 2019 and 2024. This indicates a significant shift in how both patients and physicians are managing obesity." }, "name" : "How is the GLP-1 surge impacting bariatric surgery rates?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Real-world usage shows more complex results than clinical trials. While clinical trials showed averages of 15% to 20% weight loss, real-world data reveals that patients who stopped taking the drugs early lost only 3.6% of their body weight, and those who remained on therapy for a full year lost about 12%." }, "name" : "Is real-world weight loss from GLP-1 drugs the same as in clinical trials?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Despite the massive surge in prescriptions, the majority of eligible patients are still not receiving these medications. In 2024, only 11.2% of patients diagnosed with overweight or obesity were prescribed a GLP-1 drug, highlighting a massive unmet need and the importance of accurate targeting." }, "name" : "Are most eligible patients receiving GLP-1 medications?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "RWD offers a comprehensive view of patient and provider journeys that clinical trials cannot capture. It allows life sciences organizations to monitor prescribing patterns, treatment persistence, true clinical outcomes, and the reasons behind adherence barriers such as side effects, cost, and insurance coverage." }, "name" : "Why is real-world data (RWD) important for studying GLP-1 therapies?" } ] } ``` ```json { "@context" : "https://schema.org", "@type" : "BreadcrumbList", "itemListElement" : [ { "@type" : "ListItem", "item" : "https://healthverity.com/", "name" : "Home", "position" : 1 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/", "name" : "Blog", "position" : 2 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals", "name" : "The GLP-1 trend: What the real-world data reveals", "position" : 3 } ] } ```